(Fixes formatting in the last bullet)
Feb 25 – Zydus Lifesciences will launch generic versions of semaglutide injections for obesity and diabetes in India after patent expiry of the Ozempic active ingredient in late March, it said on Wednesday.
(Reporting by Nishit Navin in Bengaluru; Editing by Sahal Muhammed)
Comments